Brentuximab vedotin
As of the edition of 20 October 2026, Brentuximab vedotin is an antibody drug conjugate: marketed, first approved in 2011 (US); acts on TNFRSF8, TUBB and TUBB1 and 7 more; US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Antibody drug conjugate
- Brand name
- Adcetris
- First approved
- 19 August 2011 (US)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Takeda; 4 holders in all
- Registered trials
- 176, 32 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Skin and connective tissue; Urinary and reproductive; Hormones
US protection
US protection ends in 2029.
The orphan exclusivity ends in 2029 (it covers one use only). The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
10 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product10 company-target rows are on route B because of Brentuximab vedotin.
See the 10 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TNFRSF8 | Tumor necrosis factor receptor superfamily member 8 | P28908 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 6 | 3 | 2 |
| Phase 1 | 28 | 16 | 1 | 9 |
| Phase 2 | 114 | 52 | 31 | 19 |
| Phase 3 | 17 | 4 | 9 | 2 |
| Phase 4 | 4 | 3 | 1 | 0 |
| All trials | 176 |